Our Take
Insulet lost on procedure, not merit—a reminder that trade secret lawsuits have hard statute-of-limitations teeth, and sleeping on enforcement costs real money.
Why it matters
Medtech companies rely heavily on trade secret protection for device designs and algorithms. This ruling clarifies that courts will penalize delayed disclosure claims, not just weak evidence, raising the stakes for companies to monitor and act on suspected theft faster.
Do this week
IP counsel: audit your trade secret incident logs and establish a written policy for when suspected misappropriation triggers immediate legal notice (within 90 days) so statute-of-limitations defenses don't kill future claims.
Appeals court kills $59M verdict on timing grounds
A U.S. appeals court has overturned Insulet's $59 million trade secret verdict against EOFlow, finding that Insulet filed its lawsuit too late. The court's ruling hinged not on whether EOFlow actually misappropriated Insulet's secrets, but on when Insulet should have discovered the alleged theft and therefore when the statute of limitations began to run.
According to the appeals panel, Insulet's delay in filing—measured against the point at which a reasonable company would have known about the trade secret breach—crossed the threshold that bars recovery. The decision does not address the underlying merits of whether EOFlow used Insulet's proprietary information.
Statute of limitations now a medtech IP flashpoint
Trade secret protection is foundational to medtech strategy. Unlike patents, which carry a clear filing deadline, trade secrets can theoretically last forever if kept confidential. But that permanence comes with a catch: once a company should have known about a breach, the clock starts ticking.
This ruling strengthens the hand of defendants who can argue delayed discovery. It also shifts burden onto plaintiffs to document exactly when they first had reasonable notice of misappropriation. For Insulet, a $59 million judgment evaporated not because the theft was unproven but because the company sat on the information too long.
The decision signals that courts will not reward companies that move slowly on suspected IP theft. For medtech firms with long product development cycles and distributed teams, the implication is stark: you need real-time visibility into competitive hiring, patent applications, and device specifications, and you need to act within weeks, not months.
Tighten trade secret workflows now
If your company manufactures or designs medical devices, competitive intelligence and legal response timelines are no longer nice-to-have. Document what you know and when you know it. Establish a threshold—such as a hire from your team by a competitor, or a public disclosure that mirrors your unpublished work—that triggers a 48-hour legal review and a decision to file or disclose the secret.
Consider also whether ongoing trade secret protection is worth the litigation risk. Patents are slow but definitive. Trade secrets are durable but now exposed to procedural dismissal if you miss the window. For device algorithms and manufacturing processes with a 3–5 year competitive advantage window, a hybrid strategy (patent what you can, secret what you can't) may reduce exposure to the kind of loss Insulet just took.